A topical dosage form is a medication that is applied to a specific location on the body or body, typically body surfaces such as skin or mucous membranes, to treat ailments. Topicals include various pharmaceutical products such as:
Global regulators address both topical and oral dosage forms similarly by differentiating between solid and liquid drug products. Table 1999 of the FDA's 1 Container Closure Guidelines assigns topical powders to the same class as oral tablets and capsules and concludes that there is a low level of concern. For packaging interactions, it is based on the likelihood of a packaging-dosage form interaction occurring and the least concern associated with the route of administration.
This lower risk classification was recruited in USP <1664>, topical (and oral) powders move "one notch down" in terms of risk due to a lower estimate of the likelihood of a pack-dosage form interaction. Given this classification, Table 2 of the FDA Guidelines states that minimal chemical or biological tests are required and a reference in line with indirect food additive regulations is sufficient. Similarly, the European Medicines Agency's (EMEA) Instant Packaging Guidelines states that packaging systems for solid topical (and oral) dosage forms (and their building materials) require minimal testing (to ensure that the packaging system is fully defined (general information) and their safe use. It is necessary to make sure it meets the relevant mandatory specifications.
Liquid topicals, particularly solutions and suspensions, are classified as having a moderate concern for packaging interactions based on the likelihood of a package-dosage form interaction occurring and the least concern associated with the administration route. Given this classification, Table 2 of the FDA Guidelines states that minimal chemical or biological tests are required and that a reference to indirect food additive regulations is typically sufficient if the liquid topical is aqueous-based. However, if the drug product contains co-solvents (or is expected to extract a larger amount of substance from the water), additional extractable information may be required.
Alternatively, the European Medicines Agency's (EMEA) Emergency Packaging Guidelines reveal that packaging systems for liquid topicals (and their building materials) may require extensive testing, including extraction studies, migration studies, and toxicological assessment to ensure their safe use.
Finally, appropriate tests for the selection and qualification of packaging materials and systems applicable to topical dosage forms are described in various mandatory USP chapters, including <660> (glass), <661.1> and <661.2> (polymers) and <381. > (elastomers).
As noted for other solid dosage forms, solid topicals can act as a suitable “sink” for packaging derived exudates (and environmental impurities) through a typical suction process (in response to the "active leakage" that occurs for a liquid drug product). Therefore, leaky profiling of a solid topical drug product is an important part of the safety assessment.
Although classified similarly by regulators, liquid topical and oral dosage forms can differ greatly in composition and therefore present different challenges from a removable and leaky perspective. Based on the composition, he predicts that the main topical grades (creams, ointments, and lotions) will have a greater "leaking power" than the larger liquid oral grades (solutions, suspensions, emulsions); Therefore, when in general and all other variables are equal, liquid topicals will contain higher levels of leachate than a liquid oral one.
More specifically, however, liquid topicals will present a greater analytical challenge than liquid orals, particularly in terms of their ability to screen drug product for leaks at respective reporting thresholds such as EEC. Therefore, it can be anticipated that extractable studies in general and simulation studies in particular will have greater applicability to liquid topicals versus liquid orals, which poses their own difficulty in creating and justifying suitable simulating solvents for liquid topicals.
They are successful and practical extractables for topical dosage forms, and performing leaky assessments requires excellence in strategic planning (for example, ensuring the correct use of extraction or leach studies), study design (for example, setting up and justifying the appropriate simulation solvent). Extensive experience in study execution, particularly in analytical testing, requires a deep understanding of extractable and leachable material.
EUROLABhas developed extensive expertise in designing and implementing chemical testing programs that utilize state-of-the-art analytical techniques, highly trained and competent analytical scientists, and knowledgeable study directors. EUROLABhas a long history of successfully partnering with manufacturers and sellers of pharmaceutical products and packaging that use topical forms to effectively and efficiently secure regulatory approval for their products.
EUROLAB, with its highly expert team and internationally accredited laboratories, Topical Dosage Forms Test It performs all test, analysis, measurement, evaluation and report generation services completely and reliably.
To get an appointment, to get more detailed information or to request an evaluation, you can ask us to fill in our form and reach you.
